［1］XIE CY,WAN XZ,QUAN HT,et al.Preclinical characterization of anlotinib，a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor［J］.Cancer Sci,2018,109(4):1207-1219.
［2］LIN BY,SONG XM,YANG DW,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2，PDGFRβ and FGFR1［J］.Gene,2018,654:77-86.
［3］SUN Y,NIU W,DU F,et al.Safety,pharmacokinetics,and antitumor properties of anlotinib，an oral multi-target tyrosine kinase inhibitor,in patients with advanced refractory solid tumors［J］.J Hematol Oncol,2016,9(1):105.
［4］HAN B，LI K，ZHAO Y,et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small cell lung cancer：A multicenter，randomized phase Ⅱ trial（ALTER0302)［J］.British Journal of Cancer,2018,118（5）：654-661.
［5］HAN B，LI K，WANG Q，et al.Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer.The ALTER0303 phase 3 randomized clinical trial［J］.JAMA Oncol,2018，4（11）：1569-1575.
［6］WANG ZH,HAN BH,LI K,et al.Clinical outcomes of patients with or without common AEs in anlotinib cohort：Subgroup analysis of the ALTER0303 trial［R］.American:American Society of Clinical Oncology(ASCO),2019.
［7］SHI JH,HAN B,LI K,et al.The efficacy of anlotinib in squamous cell carcinoma(SCC) patients with or without hypertension in ALTER0303:Anlotinib as a third-line therapy in patients with advanced non-small cell lung cancer(NSCLC)［J］.Journal of Clinical Oncology，2019,37(15_suppl):e20503.
［8］WANG LL,HE Z,YANG S,et al.The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer（NSCLC)：A subgroup analysis of ALTER0303 trial［J］.Transl Lung Cancer Res，2019,8(5):575-583.
［9］LU J，ZHONG H，WU J,et al.Circulating DNA-based sequencing guided anlotinib therapy in non-small cell lung cancer［J］.Advanced Science,2019,8(19):1900721.
［10］CHENG Y，WANG Q，LI K，et al.Anlotinib as third-line or further-line treatment in relapsed SCLC：A multicentre，randomized，double-blind phase 2 trail［J］.Journal of Thoracic Oncol，2018，13(10):351-352.
［11］CHENG Y,WANG QＭ,LI K,et al.Anlotinib as third-line or further-line treatment inrelapsed SCLC:A multicentre，randomized，double-blind phase 2 trial［R］.The Kingdom of Spain:World Conference on Lung Cancer(WCLC),2019.
［12］CHENG Y,WANG Q,LI K,et al.Overall survival（OS) update in ALTER1202：Anlotinibas third-line or further-line treatment in relapsed smallcell lung cancer（SCLC)［J］.Annals of Oncology，2019,30(5):711.
［13］CHENG Y,WANG QM,LI K，et al.The impact of anlotinib for relapsed SCLC patients with brain metastases:A subgroup analysis of ALTER1202［J］.J Thoracic Oncol,2019,14(10)：823-824.
［14］WANG Q,CHENG Y,LI K，et al.Effect of alotinib in advanced smallcell lung cancer patients previously received chemoradiotherapy：A subgroup analysis in ALTER1202 trail［J］.J Thoracic Oncol，2019,14(10)：211.
［15］LI K,CHENG Y,WANG Q,et al.Quality of life in ALTER1202 trial of anlotinib as third-or further line therapy for advanced small cell lung cancer（SCLC)：A post-hoc analysis［J］.J Thoracic Oncol,2019,14(10):816.
［16］ANTONIOU G，LEE ATJ，HUANG PH，et al.Olaratumab in soft tissue sarcoma-current status and future perspectives［J］.European Journal of Cancer，2018,92：33-39.
［17］CHI Y,YAO Y,WANG S,et al.Anlotinib for metastasis soft tissue sarcoma：A randomized，double-blind，placebo-controlled and multi-centered clinical trial［J］.J Clinoncol,2018,36(15):11503.
［18］CHI Y,YAO Y,WANG S,et al.Efficacy of anlotinib in advanced soft tissue sarcoma by prior lines of the therapy，age and dose modification［R］.Germany:European Society for Medical Oncology(ESMO),2018.
［19］CHI Y,YAO Y,FANG Z,et al.Efficacy and safety of anlotinib in advanced leiomyosarcoma：Subgroup analysis of a phase Ⅱb trial（ALTER0203)［J］.Annals of Oncology，2019,30(5):694.
［20］FANG A,YAO Y,CAI JQ,et al.The effect of treatment line on the efficacy of anlotinib hydrochloride in advanced alveolar soft part sarcoma patients［J］.Annals of Oncology，2019,30(5):694-695.
［21］CHI Y,YAO Y,WANG S,et al.Evaluation of hypertension and hand-foot syndrome as marker of anlotinib efficacy in advanced soft tissue sarcoma［R］.Germany:European Society for Medical Oncology(ESMO),2018.
［22］HUANG J,XIAO JX,FANG WT,et al.Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma（ESCC)：A randomized，double-blind，multicenter phase Ⅱ trial［R］.American:American Society of Clinical Oncology Gastrointestinal(ASCOGI),2019.
［22］ DUTTON SJ,FERRY DR,BLAZEBY JM,et al.Gefitinib for oesophageal cancer progressing after chemotherapy（COG)：A phase 3，multicentre，double-blind，placebo-controlled randomised trial［J］.Lancet Oncol,2014,15(8):894-904.
［23］HUANG J,XIAO JX,FANG WT,et al.Anlotinib in chemotherapy-refractory metastatic esophageal squamous cell carcinoma（ESCC)：A randomized，double-blind，multicenter phase Ⅱ trial［J］.Journal of Clinical Oncology，2019，37(4):Abstr 95.
［24］宋岩.高血压与安罗替尼治疗二线及以上晚期食管鳞癌的疗效相关性分析［R］.厦门：中国临床肿瘤学会（CSCO),2019.
SONG Y.Analysts is of the correlation between hypertension and the efficacy of anlotinib in the treatment of second-line or further-line treatment advanced esophageal squamous cell carcinoma［R］.Xiamen：Chinese Society of Clinical Oncology（CSCO),2019.
［25］中国临床肿瘤学会(CSCO)甲状腺癌专家委员会，中国研究型医院学会甲状腺疾病专业委员会，中国医师协会外科医师分会甲状腺外科医师委员会,等.碘难治性分化型甲状腺癌的诊治管理共识(2019年版)［J］.中国癌症杂志，2019，29（6):476-480.
The Thyroid Cancer Expert Committee of the Chinese Society of Clinical Oncology（CSCO)，the Thyroid Disease Professional Committee of the Chinese Research Hospital Association，the Thyroid Surgeon Committee of the Surgical Branch of the Chinese Medical Doctor Association Consensus on Diagnosis，et al.Treatment and management of iodine refractory sexual differentiation thyroid cancer（2019 version)［J］.Chinese Journal of Cancer，2019，29（6)：476-480.
［26］VEIGA LH,NETA G,ASCHEBROOK-KILFOY B,et al.Thyroid cancer incidence patterns in San Paulo,Brazil,and the U.S. SEER program，1997-2008［J］.Thyroid,2003,23(6):748-757.
［27］CHI Y.Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma：A randomized，double-blind，multicenter phase Ⅱ trial［J］.Ann Oncol，2020，31（suppl_6）：S1347.
［28］LI D，TANG P，CHEN X，et al.Anlotinib treatment in locally advanced or metastatic medullary thyroid carcinoma：A multicentre，randomised，double-blind，placebo-controlled phase Ⅱb trial［J］.J Clin Oncol，2019，37(15)：6019.
［29］JACOBSEN J,GRANKVIST K,RASMUSON T,et al.Expression of vascular endothelial growth factor protein in human renal cell carcinoma［J］.BJU Int,2004,93(3):297-302.
［30］ZHOU AP，BAI Y，SONG Y，et al.Anlotinib in metastatic renal cell carcinoma(mRCC)with a previous anti-VEGFR TKI：Preliminary results from a multicenter，phase Ⅱ trial［J］.J Clin Oncol，2016，34(15)：e16082.
［31］ZHOU AP，MA J，BAI Y，et al.Anlotinib versus sunitinib as first line treatment for metastatic renal cell carcinoma(mRCC)：Preliminary results from a randomized phase Ⅱ clinical trial［J］.J Clin Oncol，2016，34(15)：4565.
［32］ZHOU A,SUN Y,ZHANG W,et al.Anlotinib for advanced hepatocellular carcinoma：Interim results from the phase Ⅱ ALTER0802 study［J］.Annals of Oncology，2019,30(5):288-289.
［33］Medical Administration Bureau of the National Health Commission of the People's Republic of China.Guidelines for the diagnosis and treatment of primary liver cancer（2022 edition)［J］.Chinese Journal of Digestive Surgery，2022，21（2)：143-168.